A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

Lee, Dawn C; Gladwell, Daniel; Hatswell, Anthony J; Porter, Joshua; Brereton, Nic; Tate, Elaine; Saunders, Alison L

doi:10.1186/s13561-014-0006-6

Table 6 Base case results by country, one-year time horizon

From: A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

Country	Current care			Rectal diazepam			Unlicensed buccal midazolam			BUCCOLAM
Country	Costs	QALYs	No of ambulance call-outs	Costs	QALYs	No of ambulance call-outs	Costs	QALYs	No of ambulance call-outs	Costs	QALYs	No of ambulance call-outs
Scotland	€5,544	0.75030	8.31	€6,997	0.74475	11.45	€5,544	0.75030	8.31	€5,145	0.75112	7.83
Wales	€5,019	0.68030	6.23	€7,539	0.67016	9.65	€4,565	0.68231	6.05	€4,412	0.68458	5.87
Germany	€13,278	0.69522	12.99	€13,340	0.69520	13.04	N/A			€ 9,770	0.69662	9.20
Spain	€12,862	0.74736	8.34	€12,862	0.74736	8.34				€7,378	0.75543	4.69
France	€8,550	0.47491	3.02	€8,550	0.47491	3.02				€5,913	0.47516	2.07
Italy	€6,214	0.38552	3.96	€6,214	0.38552	3.96				€4,674	0.38808	2.92
Switzerland	€27,174	0.68921	2.99	€28,588	0.68916	3.15				€17,777	0.68957	1.94
Country	Incremental versus current care			Incremental versus rectal diazepam					Incremental versus unlicensed buccal midazolam
Country	Costs	QALYs	Ambulance call-outs avoided	ICER	Costs	QALYs	Ambulance call-outs avoided	ICER	Costs	QALYs	Ambulance call-outs avoided	ICER
Scotland	–€399	0.00082	0.48	Dominant ^a	–€1,852	0.00637	3.62	Dominant ^a	–€399	0.00082	0.48	Dominant ^a
Wales	–€607	0.00429	0.36	Dominant ^a	–€3,127	0.01442	3.79	Dominant ^a	–€153	0.00227	0.18	Dominant ^a
Germany	–€3,507	0.00140	3.79	Dominant ^a	–€3,569	0.00142	3.84	Dominant ^a	N/A
Spain	–€5,484	0.00807	3.64	Dominant ^a	–€5,484	0.00807	3.64	Dominant ^a
France	–€2,637	0.00025	0.95	Dominant ^a	–€2,637	0.00025	0.95	Dominant ^a
Italy	–€1,540	0.00256	1.03	Dominant ^a	–€1,540	0.00256	1.03	Dominant ^a
Switzerland	–€9,397	0.00036	1.05	Dominant ^a	–€10,811	0.00041	1.21	Dominant ^a

ICER = incremental cost-effectiveness ratio; N/A = not applicable as unlicensed buccal midazolam is not used in these countries; QALY = quality-adjusted life-year.
^a Dominant means that BUCCOLAM is both cost saving and results in positive outcomes when compared with the relevant comparator.

Back to article page

ISSN: 2191-1991

Contact us

Submission enquiries: camille.lumabas@springernature.com
General enquiries: info@biomedcentral.com

Health Economics Review

Contact us